Max Tsai

1.0k total citations
29 papers, 784 citations indexed

About

Max Tsai is a scholar working on Surgery, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Max Tsai has authored 29 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 12 papers in Molecular Biology and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Max Tsai's work include Receptor Mechanisms and Signaling (8 papers), Phosphodiesterase function and regulation (7 papers) and Blood Pressure and Hypertension Studies (6 papers). Max Tsai is often cited by papers focused on Receptor Mechanisms and Signaling (8 papers), Phosphodiesterase function and regulation (7 papers) and Blood Pressure and Hypertension Studies (6 papers). Max Tsai collaborates with scholars based in United States, United Kingdom and Japan. Max Tsai's co-authors include Jessie L.‐S. Au, Ze Lu, Teng‐Kuang Yeh, M. Guillaume Wientjes, M. Guill Wientjes, Darren Wilbraham, Jie Wang, Tolga Uz, Dan Lü and Jie Wang and has published in prestigious journals such as PLoS ONE, NeuroImage and Cancer Research.

In The Last Decade

Max Tsai

28 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Tsai United States 14 255 227 207 116 116 29 784
Lothar Färber Germany 11 251 1.0× 101 0.4× 91 0.4× 138 1.2× 56 0.5× 16 1.1k
Jiqian Zhang China 18 235 0.9× 183 0.8× 79 0.4× 41 0.4× 287 2.5× 44 1.0k
Le Han China 13 285 1.1× 77 0.3× 74 0.4× 321 2.8× 84 0.7× 29 831
Dana Almohazey Saudi Arabia 17 212 0.8× 137 0.6× 89 0.4× 94 0.8× 132 1.1× 40 818
Zhen Liang China 16 239 0.9× 123 0.5× 91 0.4× 15 0.1× 110 0.9× 74 845
Yinan Chen China 23 581 2.3× 155 0.7× 103 0.5× 14 0.1× 102 0.9× 76 1.2k
Jin Zhu China 23 144 0.6× 123 0.5× 56 0.3× 142 1.2× 96 0.8× 68 1.3k
Rui Xia China 11 143 0.6× 177 0.8× 51 0.2× 36 0.3× 129 1.1× 25 596
Inbo Han South Korea 20 445 1.7× 131 0.6× 136 0.7× 10 0.1× 158 1.4× 27 1.1k

Countries citing papers authored by Max Tsai

Since Specialization
Citations

This map shows the geographic impact of Max Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Tsai more than expected).

Fields of papers citing papers by Max Tsai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Tsai. The network helps show where Max Tsai may publish in the future.

Co-authorship network of co-authors of Max Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Max Tsai. A scholar is included among the top collaborators of Max Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Tsai. Max Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luffer‐Atlas, Debra, Darren Wilbraham, Maria M. Posada, et al.. (2023). Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P‐Glycoprotein and Breast Cancer Resistance Protein Substrates. The Journal of Clinical Pharmacology. 64(1). 94–102.
2.
Yin, Wei, Thomas Wagner, Max Tsai, et al.. (2023). Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults. Clinical and Translational Science. 16(7). 1149–1162. 5 indexed citations
3.
Tsai, Max, Emel Serap Monkul Nery, Lisa Kerr, et al.. (2021). Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine. Clinical Pharmacokinetics. 60(6). 819–828. 13 indexed citations
4.
Komori, Mika, et al.. (2020). Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 51(3). 119–127. 4 indexed citations
5.
Blokland, Arjan, Marlies A. van Duinen, Anke Sambeth, et al.. (2019). Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. Neurobiology of Aging. 77. 37–43. 49 indexed citations
6.
Gilleen, James, Tolga Uz, Max Tsai, et al.. (2018). An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology. 238(5). 1279–1289. 41 indexed citations
7.
Takano, Akihiro, Tolga Uz, Max Tsai, et al.. (2018). A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[11C]Rolipram. Molecular Imaging and Biology. 20(4). 615–622. 11 indexed citations
8.
9.
Webb, Nicholas J.A., et al.. (2016). Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults. European Journal of Clinical Pharmacology. 72(4). 447–457. 5 indexed citations
10.
Tsai, Max, et al.. (2016). The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. European Journal of Clinical Pharmacology. 73(3). 279–288. 13 indexed citations
11.
Tsai, Max, et al.. (2016). A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. Psychopharmacology. 233(21-22). 3787–3795. 16 indexed citations
12.
Takano, Akihiro, Per Stenkrona, В. А. Степанов, et al.. (2016). A human [ 11 C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor. NeuroImage. 141. 10–17. 22 indexed citations
13.
Au, Jessie L.‐S., Peng Guo, Yue Gao, et al.. (2014). Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy. The AAPS Journal. 16(3). 424–439. 24 indexed citations
14.
Lu, Ze, Max Tsai, Jie Wang, et al.. (2014). Activity of Drug-loaded Tumor-Penetrating Microparticles In Peritoneal Pancreatic Tumors. Current Cancer Drug Targets. 14(1). 70–78. 6 indexed citations
15.
Tsai, Max, Ze Lu, M. Guillaume Wientjes, & Jessie L.‐S. Au. (2013). Paclitaxel-loaded polymeric microparticles: Quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. Journal of Controlled Release. 172(3). 737–744. 33 indexed citations
16.
Naik, Himanshu, Max Tsai, Jill Fiedler‐Kelly, Ping Qiu, & Majid Vakilynejad. (2013). A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. PLoS ONE. 8(6). e66422–e66422. 3 indexed citations
17.
Tsai, Max, Jingtao Wu, Lhanoo Gunawardhana, & Himanshu Naik. (2012). The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. International Journal of Clinical Pharmacology and Therapeutics. 50(5). 331–337. 8 indexed citations
18.
Lu, Ze, Max Tsai, Dan Lü, et al.. (2008). Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer. Journal of Pharmacology and Experimental Therapeutics. 327(3). 673–682. 83 indexed citations
19.
Tsai, Max, et al.. (2007). Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. Molecular Cancer Therapeutics. 6. 8 indexed citations
20.
Tsai, Max, Ze Lu, Jie Wang, et al.. (2007). Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel. Pharmaceutical Research. 24(9). 1691–1701. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lothar Färber Breakdown of academic impact, for papers by Jiqian Zhang Breakdown of academic impact, for papers by Le Han Breakdown of academic impact, for papers by Dana Almohazey Breakdown of academic impact, for papers by Zhen Liang Breakdown of academic impact, for papers by Yinan Chen Breakdown of academic impact, for papers by Jin Zhu Breakdown of academic impact, for papers by Rui Xia Breakdown of academic impact, for papers by Inbo Han
Rankless by CCL
2026